African Swine Fever roadmap:
Diagnostic Tests
Roadmap for the development of diagnostic tests for ASF
Download ASF Diagnostic Roadmap7
Host-pathogen interactions
Dependencies
Next steps
- 6 Immune response
- 6A Response
- 6B Cell-mediated immunity
- 12 Biomarker detection
Investigate host-pathogen interaction in ASF infection
Research Question
- To gain an improved understanding of how ASFV enters, replicates and survives in and is released from infected cells
Research Gaps and Challenges
- Determine patterns of activation of immunologically relevant host genes particularly at early stages after infection
- Identify ASFV genes and genetic determinants (group of genes like multigene families) involved in host range, virulence and pathogenicity
State Of the Art
- The primary cell types infected by ASFV are those belonging to the mononuclear- phagocytic system, including fixed tissue macrophages and
specific lineages of reticular cells. Pathological findings in acute ASF include leukopenia B and T cell lymphopenia / thrombocytopenia
lymphocyte and mononuclear cell apoptosis - ASFV exhibit temporal regulation of gene expression. ASFV virions contain enzymatic activities that contribute to early events in, and activities
critical for, viral replication in the cell cytoplasm, including RNA polymerase, nucleoside triphosphate phosphohydrolase, topoisomerase,
mRNA capping, and protein kinase activity. ASFV encodes proteins predicted to mediate virus–host interaction, virulence, and mechanisms
that enhance the ability of the virus to successfully replicate within the host, including homologs of cellular inhibitor of apoptosis (IAP), Bcl-2, I
Kappa B (IKB) myeloid differentiation primary response antigen MyD116, lectin-like, and CD2 proteins
Projects
What activities are planned or underway?
Africa's Long Depression: The Growth and Debt Crises of 1975-2000
Planned Completion date 01/03/2027
Participating Country(s):
United Kingdom
Unlocking potential: developing innovative adolescent screening visits for health promotion, prevention and treatment in low-resource settings
Planned Completion date 01/01/2028
Participating Country(s):
United Kingdom